Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mochida to Prevail through R&D, Alliance, Emphasis on Results
February 12, 2001
- Keisansho to Promote Healthcare Services as Industry
February 12, 2001
- REGULATORY NEWS IN BRIEF -2-
February 12, 2001
- Dainippon to Withdraw Aleviatin Fine Granules
February 12, 2001
- Drug Makers Must Assume Full Responsibility for Their Products
February 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 12, 2001
- Bayer Yakuhin, Meiji Seika to Comarket Ciproxan
February 12, 2001
- Japan Not to Introduce Inactivated Vaccine against Polio
February 12, 2001
- Combination Therapy with Protopic, Steroid Reported: Fujisawa Seminar
February 12, 2001
- Kyorin Establishes Subsidiary to Gain Foothold in US Market
February 12, 2001
- Serious ADR Reported for Sarpogrelate
February 12, 2001
- Daiichi Starts Drug Discovery Research in New Laboratory
February 12, 2001
- Kirin Brewery Wins Epoetin Patent Suit Against Snow Brand Milk
February 12, 2001
- Typographical Error Found in NHI Price of Lorcam Presented to Chuikyo
February 12, 2001
- Non-compliance with GCP Found in 1,529 Cases in 3-year Survey
February 12, 2001
- Fukujin Ties Up with Inagaki Yakuhin
February 12, 2001
- OTC NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -1-
February 12, 2001
- MEDICAL DEVICE NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -2-
February 12, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…